Showing results (291-300 of 390) with videos related to
Sort By:
Pageof 39
Vaccine|September 21, 2010
Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance NetworkAndrea K Boggild, Francesco Castelli, Philippe Gautret, et al.International Journal of Molecular Sciences|July 2, 2021
C9orf72 Intermediate Repeats Confer Genetic Risk for Severe COVID-19 Pneumonia Independently of AgeIsabella Zanella, Eliana Zacchi, Simone Piva, et al.Cancers|February 27, 2026
Autologous Stem Cell Transplantation in HIV-Positive and HIV-Negative Patients with Lymphoma: A Propensity Score-Matched Comparative AnalysisAlessandro Re, Margherita Oberti, Armando Stabile, et al.HIV Medicine|December 17, 2023
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effectsAlice Ranzani, Francesco Castelli, Antonio Di Biagio, et al.Journal of Travel Medicine|October 17, 2019
Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in ItalyAgnese Comelli, Niccolò Riccardi, Diana Canetti, et al.AIDS Care|February 16, 2023
Does the rapid initiation of antiretroviral therapy at HIV diagnosis impact virological response in a real-life setting? A single-centre experience in Northern ItalyNatalia Gregori, Stefano Renzetti, Ilaria Izzo, et al.Journal of Travel Medicine|February 11, 2004
Knowledge, attitudes and practices in travel-related infectious diseases: the European airport surveyKoen Van Herck, Pierre Van Damme, Francesco Castelli, et al.Journal of Travel Medicine|April 26, 2012
Travel-associated illness in older adults (>60 y)Philippe Gautret, Jean Gaudart, Karin Leder, et al.Journal of Translational Medicine|April 18, 2015
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort studyElena Raffetti, Francesco Donato, Filippo Castelnuovo, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2003
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trialFrancesco Mazzotta, Sergio Lo Caputo, Carlo Torti, et al.Pageof 39